Phase II study of carboplatin (CBDCA) and irinotecan (CPT-11) for patients with cancer of unknown primary (CUP)

被引：1
|
作者：
Ando, M., Sr.
Yonemori, K.
Yunokawa, M.
Nakano, E.
Kouno, T.
Shimizu, C.
Katsumata, N.
Tamura, K.
Arioka, H.
Fujiwara, Y.
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Yokohama Ind Accid Hosp, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.13514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13514
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I dose finding study with irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfunction
    Raymond, E
    Vernillet, L
    Boige, V
    Hua, A
    Ducreux, M
    Mekhaldi, S
    Jacques, C
    Gatineau, M
    Mignard, D
    Vergniol, JC
    Armand, JP
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S283 - S284
  • [22] A multicenter phase II study of S-1 combined with irinotecan (CPT-11) for patients with advanced/recurrent breast cancer
    Toh, U.
    Iwakuma, N.
    Otsuka, H.
    Takenaka, M.
    Ogo, E.
    Fujii, T.
    Tanaka, M.
    Shirouzu, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer
    Katsube, Takao
    Ogawa, Kenji
    Ichikawa, Wataru
    Fujii, Masashi
    Tokunaga, Akira
    Takagi, Yuh
    Kochi, Misugu
    Hayashi, Kazuhiko
    Kubota, Tetsuro
    Aiba, Keisuke
    Arai, Kuniyoshi
    Terashima, Masanori
    Kitajima, Masaki
    ANTI-CANCER DRUGS, 2007, 18 (05) : 605 - 610
  • [24] Phase II study of CPT-11 plus CDDP in patients with metastatic gastric cancer
    Narahara, H
    Imamura, H
    Ikeda, M
    Kobayashi, K
    Fujitani, K
    Kato, M
    Iwamoto, H
    Takabayashi, A
    Tsukuma, H
    Tsujinaka, T
    Furukawa, H
    Taguchi, T
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 438 - 438
  • [25] Combination phase I/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma
    Tobinai, K
    Hotta, T
    Saito, H
    Ohnishi, K
    Ohno, R
    Ogura, M
    Ariyoshi, Y
    Takeyama, K
    Kobayashi, T
    Ohashi, Y
    Shirakawa, S
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1996, 26 (06) : 455 - 460
  • [26] A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma
    Sanz-Altamira, PM
    O'Reilly, E
    Stuart, KE
    Raeburn, L
    Steger, C
    Kemeny, NE
    Saltz, LB
    ANNALS OF ONCOLOGY, 2001, 12 (04) : 501 - 504
  • [27] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC).
    Poon, D
    Chowbay, B
    Leong, SS
    Cheung, YB
    Toh, CK
    Tay, MH
    Lim, WT
    Tan, EH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 507S - 507S
  • [28] Phase I-II study of irinotecan (CPT-11) and nedaplatin (254S) in patients with advanced and recurrent cervical cancer
    Hashiguchi, Yasunori
    Tsuda, Hiroshi
    Nishimura, Sadako
    Nakata, Shinichi
    Miyama, Masato
    Yoshida, Chika
    Fukumasu, Hiroshi
    Nakamura, Tetsuo
    Sako, Hisao
    Kawamura, Naoki
    ANNALS OF ONCOLOGY, 2004, 15 : 135 - 135
  • [29] A phase II study of irinotecan (CPT-11) and doxorubicin (DXR) in patients with refractory or relapsed small-cell lung cancer (SCLC).
    Negoro, S
    Uejima, H
    Takeda, K
    Miyazaki, M
    Takihuji, N
    Hirashima, T
    Matsui, K
    Fukuoka, M
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [30] PHASE II STUDY OF IRINOTECAN (CPT-11) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED METASTATIC BREAST CANCER (MBC): KMBOG0601
    Hayashi, H.
    Tsurutani, J.
    Satoh, T.
    Sakamoto, J.
    Masuda, N.
    Tokunaga, Y.
    Yamaguchi, M.
    Tominaga, S.
    Fukuoka, M.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 121 - 121
12345